<乌鸦传媒>Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
<乌鸦传媒>Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma Motixafortide plus filgrastim increased adequate harvest rate from 9.5% to 67.5% Sep 11, 2023
<乌鸦传媒>Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
<乌鸦传媒>Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma Mezigdomide led to 41% response rate in heavily pretreated patients Aug 30, 2023
<乌鸦传媒>Nurse Suspected of Poisoning; Hospital Mask Mandates Return; Congressman's Cancer Dx Health news and commentary from around the Web gathered by 乌鸦传媒 staff Aug 30, 2023
<乌鸦传媒>WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
<乌鸦传媒>New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
<乌鸦传媒>CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
<乌鸦传媒>Novel Antibody Induces Durable Responses in Heavily Pretreated Myeloma Overall response rate of 90% in patients who received highest doses of REGN5459 Apr 18, 2023
<乌鸦传媒>Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
<乌鸦传媒>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<乌鸦传媒>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<乌鸦传媒>Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
<乌鸦传媒>FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
<乌鸦传媒>Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
<乌鸦传媒>'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<乌鸦传媒>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<乌鸦传媒>Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
<乌鸦传媒>Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myeloma At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
<乌鸦传媒>Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
<乌鸦传媒>Unprecedented PFS Improvement in Relapsed Multiple Myeloma Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
<乌鸦传媒>Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
<乌鸦传媒>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<乌鸦传媒>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<乌鸦传媒>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<乌鸦传媒>Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Product FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
<乌鸦传媒>Is Multiple Myeloma a Greater Threat to Black Patients? Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
<乌鸦传媒>Rare Case of Multiple Myeloma in Teenage Girl Successful use of affordable induction therapy with autologous stem cell transplantation Nov 09, 2021
<乌鸦传媒>Myeloma Drug Pulled From Market Just Months After Approval Data from confirmatory trial failed to make a compelling case for full FDA approval Oct 22, 2021
<乌鸦传媒>No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
<乌鸦传媒>Charles Grodin's Death From Multiple Myeloma A look at the beloved actor's highly treatable but rarely curable disease Jun 02, 2021
<乌鸦传媒>Three-Drug Regimen Reduces Myeloma Treatment Burden Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone Dec 04, 2020
<乌鸦传媒>FDA OKs Anti-BCMA Drug for Multiple Myeloma Accelerated approval for belantamab mafodotin after four other therapies Aug 06, 2020
<乌鸦传媒>Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<乌鸦传媒>New Standard for Relapsed/Refractory Multiple Myeloma? Triplet regimen significantly extended median PFS versus doublet in IKEMA study Jun 15, 2020
<乌鸦传媒>High Marks for CAR T Cells in R/R Myeloma Response rates of 70-100% with BCMA-targeted products for heavily treated disease Jun 03, 2020
<乌鸦传媒>VRd Still Reigns in Newly Diagnosed Myeloma KRd fails to prove superiority in head-to-head trial Jun 01, 2020
<乌鸦传媒>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<乌鸦传媒>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
